In breast cancer, JAK2/STAT5 activation is associated with resistance to PI3K/mTOR inhibitors, and combination therapy targeting JAK2/STAT5 and PI3K/mTOR was proposed to overcome this resistance [38]. Here, PIK3CB is linked to breast carcinoma.